Home / News / Coriell Life Sciences News & Events / Driving Precision Medicine as the New Standard of Care
Pharma Tech Outlook Top 10 Pharmacogenomics Companies 2022
View all News
March 14, 2023

Driving Precision Medicine as the New Standard of Care

Coriell Life Sciences Named Top Pharmacogenomics Company 2022

 
Coriell Life Sciences Top pharmacogenomics company awarded by Pharma Tech Outlook
 
 
Coriell Life Sciences’ President & CEO, Scott Megill was recently interviewed by Pharma Tech Outlook.
 
Unlocking the power of pharmacogenomics (PGx), – the study of how genes affect a person’s response to drugs – Coriell Life Sciences (CLS) empowers healthcare providers, pharmacists, laboratories, and individuals to better understand the efficacy and safety of medications on a personalized level, paving the way for more effective medical care.
 
“Driven by our mission to empower a healthier world, we go beyond genetic testing to improve population health, reduce costs, and simplify decision-making,” says Scott Megill, President and CEO of Coriell Life Sciences.
Read the Full Story

Complete the form below to learn more about how our medication safety program can help your employees or health plan participants.


    *required

    About

    Coriell Life Sciences (CLS), a leader in genetic science, uses innovation in precision medicine to reduce healthcare costs and empower a healthier world. With scientific expertise that spans six decades, CLS bridges the gap between genetic knowledge and clinical application and offers the most comprehensive medication risk management program on the market. Visit coriell.com, email info@coriell.com or follow @CoriellLife.